Experts shared diagnosis and management strategies for chronic pruritus at the Dermatology Days of Paris 2024 conference.

Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Polymyalgia Rheumatica (PMR).

SM-020 is under clinical development by DermBiont and currently in Phase II for Dermatosis. According to GlobalData, Phase II drugs for Dermatosis does not have sufficient historical data to build an ...